ArticleMedicine2025
Overexpression of GNPDA1 in head and neck squamous cell carcinoma: Prognostic significance, immune infiltration, and correlation with cancer cell immune evasion.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the correlation between glucosamine-6-phosphate isomerase 1 (GNPDA1) expression and prognosis, immune infiltration, and immune evasion in head and neck squamous cell carcinoma (HNSCC). We analyzed the expression of GNPDA1 in HNSCC tissues and obtained RNA sequence data from the Cancer Genome Atlas (TCGA) database. Kaplan-Meier survival analysis evaluated the relationship between GNPDA1 expression and advanced tumor stage, TNM stage, grading, and gender. Co-expressed genes with GNPDA1 were identified using TCGA data and annotated through gene ontology and Kyoto encyclopedia of genes and genomes analyses. A protein-protein interaction network was constructed using the STRING database. Single-sample gene set enrichment analysis was conducted based on TCGA and TIMER 2.0 databases to assess the correlation between GNPDA1 and immune infiltration. In addition, the location of GNPDA1 in tumor cell and immune cell structures was identified by the tumor immune stromal cells helper database, and potential protein-interacting molecules of GNPDA1 were elucidated in the STRING database. Potential GNPDA1 gene functions were assessed using gene set enrichment analysis. Our results indicate that the expression of GNPDA1 is elevated in HNSCC tissues (P < .05). GNPDA1 expression was positively correlated with tumor malignancy (P < .05) and negatively correlated with patient prognosis (P < .05). There was a significant correlation between high expression of GNPDA1 and advanced tumor stage, N-stage, or G-grade, and it was associated with gender. High GNPDA1 expression was associated with increased infiltration of resting CD4+T cells, macrophages M1 and M2, resting natural killer cells, monocytes, eosinophils, and naïve B cells (P < .05). In contrast, low GNPDA1 expression was associated with increased infiltration of activated natural killer cells, neutrophils, activated mast cells, macrophages M0, plasma cells, activated dendritic cells, CD8+T cells, memory B cells, regulatory T cells (Tregs), and naïve CD4+T cells (P < .05). In addition, GNPDA1 was observed to be closely associated with various immune evasion-related genes in HNSCC. The results of this study suggest that GNPDA1 can serve as a potential prognostic marker and therapeutic target for HNSCC and may be a key gene mediating immune evasion in HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.